Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01833806
Other study ID # BM018
Secondary ID P110039/S2
Status Completed
Phase N/A
First received
Last updated
Start date September 2013
Est. completion date January 14, 2022

Study information

Verified date April 2023
Source InSightec
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.


Description:

As part of the PMA # P110039 review process and approval, InSightec was requested to conduct a post-approval study. Patients will be treated following the approved commercial treatment guidelines. For this study, participating sites will use the ExAblate device for the administration of the ExAblate treatment. This study will be performed on either 1.5T or 3T MR scanners. For this study, a total of 70 patients meeting the approved commercial guidelines will be enrolled and treated with the ExAblate system at from 7 to 10 sites. The proportion of responders is expected to be at least 30% greater than the proportion of subjects experiencing pain progression (i.e., 60% vs. 30%). Additionally, at the 3 month visit, an analysis of both the safety and efficacy profiles will be compared to the original PMA pivotal study group.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date January 14, 2022
Est. primary completion date January 14, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women age 18 and older - Patients who are able and willing to give consent and able to attend all study visits - Patients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions: - Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician - those for whom their treating physician would not prescribe radiation or additional radiation treatments - patients who refuse additional radiation therapy. - Patient with NRS (0-10 scale) pain score = 4 irrespective of medication - Targeted bone/tumor interface are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5) - Targeted bone/tumor interface (most painful lesion) size up to 55 cm2 in surface area - Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin. - Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible - Able to communicate sensations during the ExAblate treatment - Patients on ongoing chemotherapy regimen at the time of eligibility: 1. with same chemotherapy regime (as documented from patient medical dossier), And 2. Worst pain NRS still = 4 And 3. do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study. Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy. - No radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration. - Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated. - Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated). Exclusion Criteria: - Patients who either - Need surgical stabilization of the affected bony structure (>7 fracture risk score, see Section 7.4) OR - Targeted tumor is at an impending fracture site (>7 on fracture risk score, see Section 7.4). OR - Patients with surgical stabilization of tumor site with metallic hardware - More than 5 painful lesions, or more than 1 requiring immediate localized treatment - Targeted (treated) tumor is in the skull - Patients on dialysis - Patients with life expectancy < 3-Months - Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study. - Patients with unstable cardiac status including: - Unstable angina pectoris on medication - Patients with documented myocardial infarction within six months of protocol entry - Congestive heart failure requiring medication (other than diuretic) - Patients on anti-arrhythmic drugs - Severe hypertension (diastolic BP > 100 on medication) - Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. - Patients with an active infection or severe hematological, neurological, or other uncontrolled disease. - Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease - KPS Score < 60 (See "Definitions" below) - Severe cerebrovascular disease (multiple CVA or CVA within 6 months) - Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.) - Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder. - Are participating or have participated in another clinical trial in the last 30 days - Patients initiating a new chemotherapy regime for pain purposes only, or radiation (for the targeted most painful lesion) within the last 2 weeks Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy. - Patients unable to communicate with the investigator and staff. - Patients with persistent undistinguishable pain (pain source unidentifiable of the targeted lesion) - Patient whose bone-lesion interface is < 10-mm from the skin - Targeted (most painful) tumor NOT visible by non-contrast MRI, - Targeted (most painful) tumor Not accessible to ExAblate - The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ExAblate MRgFUS
Focused Ultrasound Ablation

Locations

Country Name City State
United States University of Virginia Charlottesville Virginia
United States City of Hope Duarte California
United States MD Anderson Houston Texas
United States University of California Los Angeles Los Angeles California
United States Weill Cornell Medical Center New York New York
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States University of California San Francisco San Francisco California
United States Stanford University School of Medicine Stanford California

Sponsors (1)

Lead Sponsor Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Numerical Rating Scale (NRS) for Pain Score Patient pain intensity on an 11-point Numerical Rating Scale from 0 to 10 in which 0 is no pain and 10 is the worst pain you can imagine. The NRS was administered pre-treatment and post-treatment. The trajectory of change was presented graphically. Three months post treatment
Other Quality of Life (QOL) as Measured by Change in Brief Pain Inventory - Interference (BPI) From Baseline The BPI-QOL questionnaire is designed to show the severity and interference of pain in the lives of patients. This is a 7-item questionnaire that asks respondents the extent to which pain interferes with their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life using a 0-10 numerical rating scale in which 0 represents 'does not interfere' and 10 indicates 'completely interferes'. Responses to the 7 items are averaged to form the pain interference scale score. Thus, the minimum possible is 0 and the maximum possible is 10 points. Lower scores are better, showing less interference in daily activities while higher scores show more interference and hence worse outcomes. Baseline, 1 Month post treatment, 2 Month post treatment, 3 Month post treatment.
Primary Proportion of Responders The statistical hypothesis is that the proportion of responders will be significantly greater than the proportion of subjects experiencing pain progression (worsened pain or increased pain medications usage). Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), subjects were rated as a Responder or as having Pain Progression. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use. Pain Progression was increased pain of two (2) or more points. Three months post treatment
See also
  Status Clinical Trial Phase
Terminated NCT01586273 - Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases N/A
Completed NCT02609828 - Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Phase 3
Completed NCT04592887 - Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases N/A
Recruiting NCT02231476 - Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients Phase 2
Recruiting NCT02426697 - Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy Phase 3
Completed NCT00334139 - Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase 4
Completed NCT01784393 - Chemoradiation for Bone Metastasis Phase 2
Terminated NCT02999152 - Validation of Radio-induced Damage Biomarkers N/A
Not yet recruiting NCT02480634 - Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Phase 4
Completed NCT02784652 - Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors Phase 2
Completed NCT02774213 - A Study to Collect Data About Analgesia in Patients With Bone Metastasis
Completed NCT02673060 - A Trial of MBC-11 in Patients With CIBD Phase 1
Completed NCT02876731 - Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS) N/A
Recruiting NCT02705157 - The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones N/A
Completed NCT01309048 - Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases Phase 1/Phase 2
Completed NCT01062503 - Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC N/A
Completed NCT00610272 - Optimization of Radiotherapy in Treatment of Painful Bone Metastasis Phase 3
Completed NCT01998607 - Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw N/A
Recruiting NCT02876991 - Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma N/A
Completed NCT02293642 - Bone Pain Score Validation Initiative